Health Trials

Clinical trials

6

Search and review clinical trials. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Recruiting

RENAISSANCE 2: SPN-817 Phase 2, Double-Blind, Placebo-Controlled Study in Adults With Focal Onset Seizures

This is a Phase 2 double-blind, randomized, placebo-controlled, multicenter, parallel-group study to evaluate the efficacy, safety, and tolerability of SPN-817 in adults with focal onset seizures.

Participants needed: 216
Trial details
Phase: Phase 2Age: 18-70Biological sex: AllType: InterventionalSponsor: Supernus Pharmaceuticals, Inc.Updated: Jun 1, 2026Locations: 1
Eligibility criteria

Diagnosis of treatment-resistant focal epilepsy as adjudicated by the Epilepsy S... [+5]

Has taken huperzine A within the past 6 months; [+10]

Read more
Status: Recruiting

Safety and Tolerability Study of SPN-817 in Adult Patients With Treatment Resistant Epilepsy

This study will evaluate the safety and tolerability of SPN-817 in adults with treatment resistant seizures

Participants needed: 60
Trial details
Phase: Phase 2Age: 18-70Biological sex: AllType: InterventionalSponsor: Supernus Pharmaceuticals, Inc.Updated: Apr 21, 2026Locations: 10
Eligibility criteria

A diagnosis of treatment resistant epilepsy as adjudicated by the Epilepsy Study... [+21]

Has taken huperzine A within the past year [+32]

Read more
Status: Recruiting

Double-blind, Placebo-controlled Study in Adults With Major Depressive Disorder

This study will evaluate the efficacy and safety of SPN-821 in adults with major depressive disorder

Participants needed: 230
Trial details
Phase: Phase 2Age: 18-70Biological sex: AllType: InterventionalSponsor: Supernus Pharmaceuticals, Inc.Updated: Mar 24, 2026Locations: 1
Eligibility criteria

Current diagnosis of MDD according to the DSM-5 for either single or recurrent M... [+4]

MADRS total score change of ≥ 25% from the Screening Visit to Day 1 Visit [+8]

Read more
Status: Recruiting

Evaluation of SPN-812 (Viloxazine Extended-release Capsule) in Preschool-age Children With ADHD

This study will evaluate the efficacy and safety of SPN-812 (viloxazine extended release) in children 4 to 5 years of age with ADHD.

Participants needed: 286
Trial details
Phase: Phase 4Age: 48-69Biological sex: AllType: InterventionalSponsor: Supernus Pharmaceuticals, Inc.Updated: Feb 18, 2026Locations: 47
Eligibility criteria

Is male or female 4 years 0 months of age to less than or equal to 5 years 9 mon... [+8]

Has no current condition in the opinion of the Investigator that could confound... [+18]

Read more
Status: Recruiting

Real-World Patient Experiences Using Continuous Subcutaneous Apomorphine Infusion (ONAPGOTM) in the United States:

Real-World Participants Experiences Using Continuous Subcutaneous Apomorphine Infusion (ONAPGOTM) in the United States: A Prospective, Phase 4, Multicenter, Observational Study in Parkinson's Disease

Participants needed: 120
Trial details
Age: 18+Biological sex: AllType: ObservationalSponsor: Supernus Pharmaceuticals, Inc.Updated: Oct 22, 2025Locations: 5
Eligibility criteria

Not listed

Read more
Status: Recruiting

SPN-817 Open-Label Extension Study in Adults With Focal Onset Seizures

This is a Phase 2b open-label extension study to evaluate the long-term safety and efficacy of SPN-817.

Participants needed: 100
Trial details
Phase: Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: Supernus Pharmaceuticals, Inc.Updated: Oct 10, 2025Locations: 1
Eligibility criteria

Completed antecedent SPN-817 double-blind study [+1]

Has current nonepileptic events that could be confused by the participant and/or... [+1]

Read more